Epilepsy biotech Marinus Pharmaceuticals files for a $63 million IPO

Comment

Shutterstock photo

Marinus Pharmaceuticals, a clinical-stage biotech developing an add-on therapy for adults with epilepsy, filed on Monday with the SEC to raise up to $63 million in an initial public offering. The New Haven, CT-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol MRNS. Marinus initially filed confidentially on April 4, 2014. Stifel and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com